Company: LIMN
Filing Date: 2025-06-02
Form Type: 8-K/A
Source: 0001104659-25-055078
Chunk: 2

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-02
Form: 8-K/A
Chunk 2
---
 update or a discussion of any other
developments at the Company or its subsidiaries, including Liminatus, subsequent to the filing date of the Original Report. The information
previously reported in or filed with the Original Report is hereby incorporated by reference to this Amendment No. 1.

Unless otherwise stated or unless the context otherwise requires, the
terms “we,” “us,” “our,” the “Registrant,” the “Combined Company,” the “Company”
and “ParentCo” refer to Liminatus Pharma, Inc. (formerly known as Iris Parent Holding Corp.), a Delaware corporation,
after giving effect to the Business Combination, and where appropriate, our wholly-owned subsidiaries (including Liminatus Pharma, LLC)
following the Closing Date (as defined in the Original Report). Furthermore, unless otherwise stated or unless the context otherwise requires,
references to “Iris” refer to Iris Acquisition Corp (formerly known as Tribe Capital Growth Corp I), a Delaware corporation,
prior to the Closing Date, and references to “Liminatus” refer to Liminatus Pharma, LLC, a Delaware limited liability company,
prior to the Closing Date. All references herein to the “Board” refer to the board of directors of the Company.

Item 2.01. Completion of Acquisition or Disposition of Assets.

The disclosure set forth in
the “Introductory Note” above is incorporated into this Item 2.01 by reference.

In connection with the vote
at the Special Meeting on March 4, 2025, public stockholders holding 59,844 Iris Class A Shares exercised their right to redeem
such shares for a pro rata portion of the funds in the trust account established at the consummation of Iris’ initial public offering
(the “Trust Account”). As a result, approximately $702,359 (approximately $11.74 per share) was removed from the Trust Account
to pay such holders. Immediately after giving effect to the redemption of 59,844 Iris Class A Shares in connection with the Business
Combination, there were 114,633 public shares and 6,900,000 public warrants outstanding.

Upon the consummation of the
Business Combination, Iris’s Class A common stock, units and public warrants ceased trading on the OTC Pink Marketplace,
and ParentCo Common Stock and ParentCo Public Warrants began trading on The Nasdaq Stock Market (“Nasdaq”) on May 1,
2025, under the symbols “LIMN” and “LIMNW,” respectively.

<div